OBR Daily Commentary

forumImage

CMS Takes the Lead In Oncology Payment Reform

(Managed Care) October 2015 - Only Medicare has the heft and reach to make cancer services more value-based, and recent reforms aim to do just that. Insurers keep close watch.

Read Article arrow

Dean Gesme, MD (Posted: October 16, 2015)

quotesThe OCM results will need to be interpreted with caution as CMMI has been unwavering in rejecting applications in which outreach care is involved. CMMI requires applicants to separate from all such arrangements involving critical access care facilities and from any other institutions which are unwilling or unable to also complete the entire CMMI OCM burdensome application process. My practice, including over 85 oncology providers, has been rejected even though only a fraction of one percent of our revenues derived from such outreach arrangements. We are simply unwilling to deprive our Outreach Medicare patients of rural access in order to keep CMMI's OCM data "pure".quotes

Add Comment 2 Comment
forumImage

FDA Approves Pembrolizumab for Lung Cancer

(Medscape Medical News) Oct 2, 2015 - The programmed death (PD-1) inhibitor pembrolizumab (Keytruda, Merck & Co) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the second immunotherapy available for this tumor type.

Read Article arrow

Dean Gesme, MD (Posted: October 05, 2015)

quotesThis approval presents an epic problem: to obtain a companion diagnostic (pembro) or not to obtain a companion diagnostic (nivo). Given the controversies over various immune biomarkers, tumor heterogeneity, and predictive validity of the campanion diagnostic, this should be an interesting fight for market superiority with flavors of patient demand, payer mandates, and clinical science all colliding!quotes

Add Comment 1 Comment
forumImage

ED Induced by Prostate Biopsy Likely 'Underestimated'

(Medscape Medical News) Oct 1, 2015 - A study of men with elevated PSA indicates that there is a loss of erectile function (ED) in the weeks and months after needle biopsy.

Read Article arrow

Dean Gesme, MD (Posted: October 02, 2015)

quotesOncologists would do well to pose more questions of the urology community concerning ED and infections arising from prostatic biopsies in order to better inform our prostate cancer patients opting for active surveillance and to better inform our primary care colleagues.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...